Plain-English translation of NCT06616584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding a new immunotherapy drug called to two standard chemotherapy drugs ( and ) helps people with advanced non-small cell lung cancer live longer. You would be randomly assigned to receive either the two standard chemotherapy drugs alone, or those drugs plus the new medication. The study will compare how well each approach works and how side effects differ between the two groups.
Many people with advanced lung cancer eventually stop responding to standard chemotherapy and immunotherapy treatments. This trial is exploring whether adding this medication to chemotherapy might help patients whose cancer has become resistant to previous treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one receiving two chemotherapy medications ( and ), and the other receiving those same two drugs plus . All medications are given intravenously (through your veins) on the first day of each 21-day cycle, and you'll take a steroid pill for three days at the start of each cycle. You will have regular CT or MRI scans and blood tests throughout the study to monitor how your cancer responds and track any side effects, and the study will continue until your cancer progresses or you experience unacceptable side effects.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
United States